Powered by
-
REGN Stock Chart
Historical REGN Prices
Regeneron Pharmaceuticals Stock Analysis
Rating: Sell
Total Grade: D
Analysis Breakdown
| REGN Stock Grade: | D |
| Fundamental Grade: | C |
| Quantitative Grade: | F |
| REGN Earnings | |
| Earnings Growth: | D |
| Earnings Momentum: | F |
| Earnings Surprises: | B |
| Analyst Earnings Revisions: | B |
| REGN Financial Information | |
| Sales Growth: | A |
| Operating Margin Growth: | D |
| Cash Flow: | C |
| Return on Equity: | A |
Regeneron Pharmaceuticals Stock: Weekly View
| This Week: | D |
|---|---|
| Last Week: | D |
| Two Weeks Ago: | D |
REGN Stock predictions, Articles, and Regeneron Pharmaceuticals News
- From InvestorPlace
- From the Web
-
Tread Very Carefully When Investing in AnaptysBio Inc - March 28, 2018
ANAB is up on positive clinical studies posted in the last few months. But the small sample size and risks ahead could hurt the stock in the near term. Continue…
-
10 Stocks to Ride Out the Market Storm - February 6, 2018
Put these tickers on a list of stocks to buy here in the midst of market-wide carnage. They're likely to recover first and best once the selloff settles. Continue…
-
9 More Stocks Still Growing Faster Than Amazon - January 2, 2018
If you're looking for growth, Amazon.com isn't your only investment choice. These names are on a tear as well, and could be worthy additions to your portfolio. Continue…
-
Lackluster Quant Score Penalize Regeneron Pharmaceuticals (REGN) Rating - December 11, 2017
Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. The methods for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 6 months. Continue…
-
Sector ETF and Stock Winners in the 10 Years Since the Great Recession - December 7, 2017
While most of the sectors have flourished over the past decade, consumer discretionary and information technology have led the way . Continue…
-
Regeneron Pharmaceuticals (REGN) a Hold on Vapid Quant Score - December 4, 2017
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is classified as a component of the 350 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. REGN's market value is $40.1 billion which places it in the top decile in its industry group. The current Portfolio Grader ranking for REGN puts it 188 among the 350 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 428 among the 782 companies in the sector, and number 2,601 in the nearly 5,000 company Portfolio Grader universe. Continue…
-
Regeneron Pharmaceuticals (REGN) a Hold on Uninspiring Industry Group Rank - November 27, 2017
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is ranked as a Hold using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing approach. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 5 months. Continue…
-
Regeneron Pharmaceuticals (REGN) a Hold on Poor Industry Group Rank - November 20, 2017
Portfolio Grader currently ranks Regeneron Pharmaceuticals Inc (NASDAQ:REGN) a Hold. With proprietary fundamental and quantitative analytical tools developed by Louis Navellier, this analytical tool evaluates nearly 5,000 stocks weekly. This represents no change from the previous week and is the same ranking REGN has had from Portfolio Grader for 5 months. Continue…
-
Weak Quant Score Restrict Regeneron Pharmaceuticals (REGN) Rating - November 13, 2017
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is one of 349 companies within the Biotechnology GICS industry group, which is in turn part of the 782 company GICS Health Care sector. REGN has a market value of $43.4 billion which is in the top 10% of its industry group. The ranking for REGN by Portfolio Grader places it 173 among the 349 companies in this industry group, giving it an above-average position; in the third quartile of the sector with a ranking of 404 among the 782 companies in the sector, and number 2,615 in the nearly 5,000 company Portfolio Grader universe. Continue…
-
Poor Quant Score Limit Regeneron Pharmaceuticals (REGN) Rating - November 6, 2017
Currently, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) has a Hold using the methodology for investing of Louis Navellier and his Portfolio Grader stock evaluator. REGN has maintained this ranking for 5 months. Continue…
